Administração em Bolus Único de Estafilocinase Não Imunogénica em Doentes com Acidente Vascular Cerebral Isquémico Agudo Dentro de 4,5-24 Horas após o Início dos Sintomas (FRIDA-CT)
Um Estudo Multicêntrico, Duplamente-cego, Randomizado, Controlado por Placebo da Eficácia e Segurança da Estafilocinase Recombinante Não-imunogénica em Doentes com Acidente Vascular Cerebral Isquémico Agudo Dentro de 4,5-24 Horas Após o Início dos Sintomas (FRIDA-CT)
Multicenter, double-blind, randomized, placebo-controlled phase III clinical trial. At the clinical sites, patients with acute ischemic stroke within 4.5-24 hours of symptom onset will be randomized to receive a single bolus injection of the recombinant non-immunogenic staphylokinase (Fortelyzin®, LLC "SuperGene", Russia) or placebo.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
The current guidelines recommended intravenous thrombolysis as the first-line treatment for acute large vessel occlusion of anterior circulation stroke within 4.5 hours of stroke onset. However, a majority of patients arrive in the hospital outside the 4.5-hour time window, who could not receive intravenous thrombolysis.
In 2020, the non-immunogenic staphylokinase was registered in Russia for the acute ischemic stroke treatment within 4,5 h after the onset of symptoms. In the FRIDA randomized clinical trial the non-immunogenic staphylokinase was non-inferior to alteplase for patients with acute ischaemic stroke. Mortality, symptomatic intracranial haemorrhage, and serious adverse events did not differ significantly between groups. Non-immunogenic staphylokinase is easy to administer with a rapid single bolus of 10 mg regardless patients' bodyweight, simplifying clinical use. In 2024, the non-immunogenic staphylokinase has been included in the updated Russian clinical guidelines for the acute ischemic stroke treatment.
A rapid (10 s) single bolus of the non-immunogenic staphylokinase in patients with acute ischemic stroke may provide significant advantages over a one-hour alteplase administration in the more rapid reperfusion in the first 24 hours after thrombolysis and a greater number of good functional outcomes. It can be assumed that the non-immunogenic staphylokinase usage in patients with acute ischemic stroke outside the 4.5-hour therapeutic window will lead to the restoration of collateral blood flow in the penumbra in comparison with standard medical management.
Therefore, FRIDA-CT trial is aimed to investigate the efficacy and safety of the non-immunogenic staphylokinase within the time window of 4.5-24 hours, wake-up stroke or no witness stroke in patients who had an acute ischaemic stroke with salvageable tissue due to large vessel occlusion.
In the multicenter, double-blind, randomized, placebo-controlled phase III clinical trial patients who had an acute ischaemic stroke due to anterior circulation large vessel occlusion (internal carotid artery, middle cerebral artery M1 and M2 segments) within 4.5-24 hours from last known well (including wake-up stroke and no witness stroke) and with salvageable tissue (ischaemic core volume <70 mL, mismatch ratio ≥1.8 and mismatch volume ≥15 mL) based on CT perfusion or MRI perfusion-weighted imaging (PWI) will be included and randomised to the non-immunogenic staphylokinase, 10 mg (single bolus) regardless patient's bodyweight or placebo group. Patients who are intended for direct thrombectomy will be excluded from the trial. Follow-up period will be 90 days.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Fase 3
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Nikolay A. Shamalov, MD, prof
- Número de telefone: +7 (499) 936-99-37
- E-mail: shamalovn@gmail.com
Estude backup de contato
- Nome: Natalya A. Marskaya
- Número de telefone: +7 (499) 936-99-37
- E-mail: marskayana@gmail.com
Locais de estudo
-
-
-
Chelyabinsk, Rússia
- Recrutamento
- Chelyabinsk Regional Clinical Hospital No. 3
-
Contato:
- Dmitry V. Popov, PhD
- E-mail: Dmitry_popov2001@mail.ru
-
Investigador principal:
- Dmitry V. Popov, PhD
-
Irkutsk, Rússia, 664079
- Recrutamento
- Irkutsk Regional Clinical Hospital
-
Contato:
- Ivan V. Korobeynikov, PhD
- E-mail: Irk.ivan@gmail.com
-
Investigador principal:
- Ivan V. Korobeynikov, PhD
-
Kazan', Rússia, 420101
- Recrutamento
- Interregional Clinical and Diagnostic Center
-
Contato:
- Dina R. Khasanova, MD, Prof
- E-mail: dhasanova@mail.ru
-
Investigador principal:
- Dina R. Khasanova, MD, Prof
-
Krasnodar, Rússia, 350086
- Recrutamento
- S.V. Ochapovsky Research Institute - Regional Clinical Hospital No. 1
-
Contato:
- Ludmila V. Timchenko, MD, prof
- E-mail: tlv2908@yandex.ru
-
Investigador principal:
- Ludmila V. Timchenko, MD, prof
-
Krasnogorsk, Rússia, 143408
- Recrutamento
- Krasnogorsk Clinical Hospital
-
Contato:
- Svetlana V. Alexandrova
- Número de telefone: +7 (498) 602-03-73
- E-mail: clairalex@mail.ru
-
Investigador principal:
- Svetlana V. Alexandrova
-
Moscow, Rússia, 108814
- Recrutamento
- Moscow Multidisciplinary Clinical Center "Kommunarka"
-
Contato:
- Denis N. Protsenko, PhD
- Número de telefone: +7 (495) 744-07-03
- E-mail: ProtsenkoDN@zdrav.mos.ru
-
Investigador principal:
- Denis N. Protsenko, PhD
-
Moscow, Rússia, 117997
- Recrutamento
- N.I. Pirogov Russian National Research Medical University
-
Contato:
- Larisa L. Korsunskaya, MD, Prof
- E-mail: neurocrimea@mail.ru
-
Investigador principal:
- Larisa L. Korsunskaya, MD, Prof
-
Nizhny Novgorod, Rússia, 603126
- Ainda não está recrutando
- N.A. Semashko Nizhny Novgorod Regional Clinical Hospital
-
Contato:
- Valentina N. Nesterova, PhD
- Número de telefone: +7 (831) 438-95-38
- E-mail: nesterova-78@mail.ru
-
Investigador principal:
- Valentina N. Nesterova, PhD
-
Orenburg, Rússia
- Recrutamento
- V.I. Voynov Orenburg Regional Clinical Hospital
-
Contato:
- Alexandr N. Chirkov, PhD
- E-mail: log82@mail.ru
-
Investigador principal:
- Alexandr N. Chirkov, PhD
-
Saint Petersburg, Rússia, 193079
- Recrutamento
- St. Petersburg Hospital for War Veterans
-
Contato:
- Maria A. Privalova, PhD
- Número de telefone: +7 (812) 670-94-44
- E-mail: privamariya@yandex.ru
-
Investigador principal:
- Maria A. Privalova, PhD
-
Saint Petersburg, Rússia, 194291
- Recrutamento
- Leningradskaya Regional Clinical Hospital
-
Contato:
- Natalya V. Zhukovskaya, MD, prof
- E-mail: nataly.lokb@mail.ru
-
Investigador principal:
- Natalya V. Zhukovskaya, MD, prof
-
Solnechnogorsk, Rússia, 141508
- Ainda não está recrutando
- Solnechnogorsk District Hospital
-
Investigador principal:
- Anton G. Koledinsky, MD, PhD
-
Contato:
- Anton G. Koledinsky, MD, PhD
- Número de telefone: +7 (496) 264-14-56
- E-mail: koledant@mail.ru
-
Tver', Rússia, 170036
- Recrutamento
- Tver Regional Clinical Hospital
-
Contato:
- Ksenia V. Khoroshavina
- Número de telefone: +7 (482) 277-54-65
- E-mail: kseniarep@mail.ru
-
Investigador principal:
- Ksenia V. Khoroshavina
-
Ulyanovsk, Rússia
- Recrutamento
- Ulyanovsk Regional Clinical Hospital
-
Contato:
- Irina V. Greshnova, PhD
- E-mail: tonuus@mail.ru
-
Investigador principal:
- Irina V. Greshnova, PhD
-
Volgograd, Rússia, 400138
- Recrutamento
- City Clinical Hospital of Emergency Medical Care No. 25
-
Contato:
- Eduard A. Ponomarev, MD, prof
- E-mail: ponomarev67@mail.ru
-
Investigador principal:
- Eduard A. Ponomarev, MD, prof
-
Yekaterinburg, Rússia, 620102
- Recrutamento
- Sverdlovsk Regional Clinical Hospital No. 1
-
Contato:
- Andrey M. Alasheev, MD, prof
- E-mail: alasheev@live.ru
-
Investigador principal:
- Andrey M. Alasheev, MD, prof
-
-
Ryazan Oblast
-
Ryazan, Ryazan Oblast, Rússia, 390039
- Ainda não está recrutando
- Ryazan Regional Clinical Hospital
-
Contato:
- Sergei B. Aksentyev, PhD
- E-mail: aksentievs@mail.ru
-
Investigador principal:
- Sergei B. Aksentyev, PhD
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Men and women aged 18 years and over;
- Acute ischemic stroke symptom onset between 4.5 to 24 hours prior to enrolment, including wake-up stroke and unwitnessed stroke, onset time refers to "last-seen normal time";
- Pre-stroke modified Rankin scale (mRS) score≤1;
- Internal carotid artery, middle cerebral artery M1 or M2 occlusion confirmed by CT/MRI, internal carotid artery, middle cerebral artery M1 or M2 being responsible for signs and symptoms of acute ischemic stroke;
- Neuroimaging: target mismatch profile on CT or MRI perfusion: ischemic core volume <70 mL, mismatch ratio≥1.8 and mismatch volume≥15 mL;
- Alberta Stroke Program Early CT score (ASPECTS) > 6;
- Baseline National Institutes of Health Stroke Scale (NIHSS) 6-25 (inclusive);
- The patient is not planned or cannot undergo thrombectomy or intravenous thrombolysis in accordance with the current version of the Clinical Guidelines;
- Written informed consent from patients or their legally authorized representatives.
Exclusion Criteria:
- Acute ischemic stroke within 4,5 h after symptom onset;
- Intended to proceed to endovascular treatment;
- Known hypersensitivity to the non-immunogenic staphylokinase;
- Convulsive seizures at the onset of the disease, if there is no certainty that the seizure is a clinical manifestation of acute ischemic stroke;
- Persistent blood pressure elevation (systolic ≥185 mmHg or diastolic ≥110 mmHg), and the inability to reduce systolic blood pressure below 180 mmHg or diastolic blood pressure below 105 mmHg;
- Blood glucose <2.8 or >22.2 mmol/L (after blood glucose level correction to the specified values, inclusion of the patient in the study is possible);
- Neuroimaging (CT, MRI) signs of intracranial hemorrhage, brain tumor, arteriovenous malformation, brain abscess, cerebral aneurysm;
- Subarachnoid hemorrhage;
- Major bleeding currently or within the past 6 months;
- Surgery on the brain or spinal cord in the last 2 months;
- Punctures of non-compressible arteries and veins in the last 7 days;
- Gastrointestinal or genitourinary bleeding in the last 3 weeks. Confirmed exacerbations of gastric ulcer and duodenal ulcer in the last 3 months;
- Platelet count below 100,000/mm3;
- Previous stroke or severe traumatic brain injury within 3 months;
- Unable to perform CT or MRI;
- History of hemorrhagic stroke or stroke of unspecified genesis;
- Multiple arterial occlusion (bilateral MCA occlusion, MCA occlusion accompanied with basilar occlusion);
- Concomitant use of indirect oral anticoagulants (warfarin) with INR > 1.7;
- Taking direct anticoagulants (heparin, heparinoids) in the previous 48 hours with an APTT value above normal;
- Taking new oral anticoagulants in the previous 48 hours with a thrombin time value above normal and the impossibility of administering the specific antagonist idarucizumab (for dabigatran) or the presence of anti-Xa activity (for rivaroxaban, apixaban and edoxaban).
- Severe liver disease, including liver failure, liver cirrhosis, portal hypertension (with esophageal varices), active hepatitis;
- Acute pancreatitis;
- Bacterial endocarditis, pericarditis;
- Arterial aneurysms, malformations of arteries and veins. Suspected dissecting aortic aneurysm;
- Cancer with an increased risk of bleeding;
- Major surgeries or severe injuries within the last 14 days, minor surgeries or invasive procedures within the last 10 days;
- Prolonged or traumatic cardiopulmonary resuscitation (more than 2 minutes);
- Hemorrhagic diathesis, including renal and hepatic failure;
- Data on bleeding or acute trauma (fracture) at the time of examination;
- Pregnant women, nursing mothers, or reluctant to use effective contraceptive measures during the period of trial.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Comparador de Placebo: Placebo
Placebo |
Placebo is given as a single intravenous bolus (within 5-10 seconds) immediately upon randomization |
|
Experimental: Non-immunogenic staphylokinase
The non-immunogenic staphylokinase is given as a single intravenous bolus, 10 mg (within 5-10 seconds) immediately upon randomization regardless patient's bodyweight |
The non-immunogenic staphylokinase is given as a single intravenous bolus, 10 mg (within 5-10 seconds) immediately upon randomization regardless patient's bodyweight
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Excellent functional outcome
Prazo: 90 days
|
The number of patients with excellent functional outcome defined as an mRS score 0-1 at 90 days |
90 days
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Ordinal distribution of mRS
Prazo: 90 days
|
Ordinal distribution of mRS at 90 days |
90 days
|
|
Functional independence outcome
Prazo: 90 days
|
The number of patients with functional independence defined by an mRS score 0-2 point at 90 days |
90 days
|
|
NIHSS change from baseline
Prazo: 7-14 days
|
NIHSS median change from baseline on discharge |
7-14 days
|
|
The rate of improvement on reperfusion
Prazo: 24 hours
|
The number of patients with recanalization of 2 and 3 points on the arterial occlusion scale (rAOL) 24 hours after drug administration according to CT (MRI) angiography, where 0 points - complete occlusion, 3 points - complete recanalization. |
24 hours
|
|
All-cause mortality
Prazo: 90 days
|
Rate of all-cause mortality within 90 days |
90 days
|
|
Poor functional outcome
Prazo: 90 days
|
The number of patients with poor functional outcome defined by an mRS score 5-6 point at 90 days |
90 days
|
Outras medidas de resultado
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Hemorrhagic transformation
Prazo: 24 hours
|
Rate of hemorrhagic transformation according to The Heidelberg Bleeding Classification within 24 hours |
24 hours
|
|
Symptomatic intracranial hemorrhage
Prazo: 24 hours
|
Rate of symptomatic intracranial hemorrhage (sICH) (as defined by The European Cooperative Acute Stroke Study III criteria [ECASSIII] and Safe Implementation of Thrombolysis in Stroke-Monitoring Study [SITS-MOST]) within 24 hours |
24 hours
|
|
Major bleeding
Prazo: 90 days
|
Rate of major bleeding at 90 days (as defined by the Bleeding Academic Research Consortium (BARC) scale: type 3 and type 5) |
90 days
|
|
Serious adverse events (SAEs)
Prazo: 90 days
|
Rate of serious adverse events (SAEs) within 90 days |
90 days
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Nikolay A. Shamalov, MD, prof, Federal Center for Brain and Neurotechnology of the Federal Medical and Biological Agency of Russia
- Diretor de estudo: Sergey S. Markin, MD, prof, LLC "SuperGene"
Publicações e links úteis
Publicações Gerais
- Gusev EI, Martynov MY, Nikonov AA, Shamalov NA, Semenov MP, Gerasimets EA, Yarovaya EB, Semenov AM, Archakov AI, Markin SS; FRIDA Study Group. Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4.5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial. Lancet Neurol. 2021 Sep;20(9):721-728. doi: 10.1016/S1474-4422(21)00210-6.
- Shamalov NA, Martynov MY, Yarovaya EB, Chefranova ZY, Kutsenko VA, Semenov AM, Ivanov SV, Semenov MP, Markin SS, Gusev EI; FORPI Study Group. Thrombolysis With the Non-Immunogenic Staphylokinase for Acute Ischemic Stroke in the FORPI Registry: An Observational Study. Stroke. 2026 Feb;57(2):394-403. doi: 10.1161/STROKEAHA.125.051115. Epub 2025 Nov 26.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- FRIDA-CT
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
The funder of the study is committed to the responsible sharing of data from FRIDA-CT trail. Data will be provided to any qualified investigator on reasonable request. Deidentified participant data will be available after the publication of the results of the completed study on request to the corresponding author.
Prazo de Compartilhamento de IPD
within 90 days after request
Critérios de acesso de compartilhamento IPD
Proposals will be reviewed and approved by the funder and Data and Safety Monitoring Board. Once the proposal has been approved, data can be transferred through a secure online platform after the signing of a data access agreement and a confidentiality agreement.
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
- CIF
- CSR
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .